Company Filing History:
1 out of 321 
1 out of 549 
Years Active: 2017
Title: HyeMi Ahn: Innovator in Monoclonal Antibody Research
Introduction
HyeMi Ahn is a notable inventor based in Daejeon, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work focuses on innovative solutions for treating various medical conditions, including cancer and liver fibrosis.
Latest Patents
HyeMi Ahn holds a patent for a monoclonal antibody that specifically binds to the TM4SF5 protein. This invention relates to a novel monoclonal antibody that targets the human TM4SF5 protein. The patent encompasses polynucleotides coding for the monoclonal antibody, an expression vector containing these nucleotides, and a transformant with the vector introduced. Additionally, it details methods for preparing the monoclonal antibody, compositions that include the antibody, and various therapeutic applications. These applications include methods for treating liver fibrosis, cancer, inhibiting cancer metastasis, and diagnosing cancer using the monoclonal antibody, along with a cancer diagnosis kit.
Career Highlights
HyeMi Ahn has worked with prominent research institutions, including the Korea Research Institute of Bioscience and Biotechnology and the SNU RDB Foundation. His experience in these organizations has contributed to his expertise in monoclonal antibody research and development.
Collaborations
HyeMi Ahn has collaborated with notable colleagues, including Se Mi Kim and Sang Jick Kim. These partnerships have enhanced his research efforts and contributed to advancements in the field.
Conclusion
HyeMi Ahn's innovative work in monoclonal antibody research demonstrates his commitment to advancing medical science. His contributions have the potential to significantly impact the treatment of serious health conditions.